MedPAC Considers Zero Copay On Generic Drugs For Low-Income Part D Beneficiaries
This article was originally published in The Pink Sheet Daily
Executive Summary
At its Nov. 3 meeting, the Medicare Payment Advisory Commission agreed with a staff proposal to legislate lower copays as a way to encourage greater use of generics among those receiving the low-income subsidy in Medicare Part D.
You may also be interested in...
Cost-Sharing Incentives Would Drive Higher Generic Drug Use By Low-Income Enrollees In Part D - MedPAC
Staff analysis found beneficiaries receiving subsidies have high brand use in categories where generics are available, including antipsychotics, diabetes, peptic ulcer treatment, cholesterol therapy.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.